UNION CITY, Calif.--(BUSINESS WIRE)--Aug. 23, 2006--Questcor Pharmaceuticals, Inc. (AMEX:QSC) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental new drug application (sNDA) seeking approval for H.P. Acthar(R) Gel (repository corticotropin injection) for the treatment of infantile spasms. Questcor anticipates that the FDA will take action on the sNDA during the second quarter of 2007. No drug is currently approved in the United States for the treatment of infantile spasms.
